Literature DB >> 25347760

Dystonia.

Ailsa Snaith1, Derick Wade.   

Abstract

INTRODUCTION: Dystonia is usually a lifelong condition with persistent pain and disability. Focal dystonia affects a single part of the body; generalised dystonia can affect most or all of the body. It is more common in women, and some types of dystonia are more common in people of Ashkenazi descent. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments, surgical treatments, and physical treatments for focal and generalised dystonia? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 19 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: acupuncture, amantadine, baclofen, benzatropine, biofeedback, botulinum toxins, bromocriptine, carbamazepine, carbidopa/levodopa, clonazepam, clozapine, deep brain stimulation of thalamus and globus pallidus, diazepam, gabapentin, haloperidol, lorazepam, myectomy (for focal dystonia), occupational therapy, ondansetron, physiotherapy, pregabalin, procyclidine, selective peripheral denervation (for focal dystonia), speech therapy, tizanidine, trazodone hydrochloride, and trihexyphenidyl.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25347760      PMCID: PMC3938056     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  36 in total

1.  Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.

Authors:  R Tintner; R Gross; U F Winzer; K A Smalky; J Jankovic
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

2.  Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.

Authors:  C L Comella; J Jankovic; K M Shannon; J Tsui; M Swenson; S Leurgans; W Fan
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

Review 3.  Classification of dystonia.

Authors:  S Fahn; S B Bressman; C D Marsden
Journal:  Adv Neurol       Date:  1998

4.  Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.

Authors:  J W Brans; R Lindeboom; J W Snoek; M J Zwarts; T W van Weerden; E R Brunt; J J van Hilten; W van der Kamp; M H Prins; J D Speelman
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

Review 5.  Pathophysiology of writer's cramp.

Authors:  Mark Hallett
Journal:  Hum Mov Sci       Date:  2006-07-21       Impact factor: 2.161

6.  Sex-related influences on the frequency and age of onset of primary dystonia. Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group.

Authors: 
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

Review 7.  Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review.

Authors:  Christopher Watts; Chad Nye; Renata Whurr
Journal:  Clin Rehabil       Date:  2006-02       Impact factor: 3.477

8.  Botulinum toxin treatment of spasmodic torticollis.

Authors:  T J Anderson; J Rivest; R Stell; M J Steiger; H Cohen; P D Thompson; C D Marsden
Journal:  J R Soc Med       Date:  1992-09       Impact factor: 5.344

Review 9.  The pathophysiology of primary dystonia.

Authors:  A Berardelli; J C Rothwell; M Hallett; P D Thompson; M Manfredi; C D Marsden
Journal:  Brain       Date:  1998-07       Impact factor: 13.501

10.  The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm.

Authors:  R Lindeboom; R De Haan; M Aramideh; J D Speelman
Journal:  Mov Disord       Date:  1995-07       Impact factor: 10.338

View more
  2 in total

Review 1.  Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.

Authors:  Maria Fiorella Contarino; Joost Van Den Dool; Yacov Balash; Kailash Bhatia; Nir Giladi; Johannes H Koelman; Annemette Lokkegaard; Maria J Marti; Miranda Postma; Maja Relja; Matej Skorvanek; Johannes D Speelman; Evelien Zoons; Joaquim J Ferreira; Marie Vidailhet; Alberto Albanese; Marina A J Tijssen
Journal:  Front Neurol       Date:  2017-02-24       Impact factor: 4.003

2.  Imepitoin for treatment of idiopathic head tremor syndrome in dogs: A randomized, blinded, placebo-controlled study.

Authors:  Nina Schneider; Heidrun Potschka; Sven Reese; Franziska Wielaender; Andrea Fischer
Journal:  J Vet Intern Med       Date:  2020-11-07       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.